Mechanisms of resistance to β-lactams in some common Gram-negative bacteria causing nosocomial infections

References

• Jones RN. Resistance patterns among nosocomial pathogens, trends over the past few years. Chest 119(Suppl. 2), S397–S404 (2001).
   PubMed Web of Science ®Google Scholar
• Ambler RP. The structure of β-lactamases. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 289(1036), 321–331 (1980).
   PubMed Web of Science ®Google Scholar
• Helfand MS, Bonomo RA. β-lactamases: a survey of protein diversity. Curr. Drug Targets Infect. Disord. 3(1), 9–23 (2003).
   PubMedGoogle Scholar
• Jacoby GA, Munoz-Price LS. The new β-lactamases. N. Engl. J. Med. 352(4), 380–391 (2005).
   PubMed Web of Science ®Google Scholar
• Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type β-lactamases. Antimicrob. Agents Chemother. 46(1), 1–11 (2002).
   PubMed Web of Science ®Google Scholar
• Winokur PL, Canton R, Casellas JM, Legarkis N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin. Infect. Dis. 32(Suppl. 2), S94–S103 (2001).
   PubMed Web of Science ®Google Scholar
• Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J. Antimicrob. Chemother. 56(1), 52–59 (2005).
   PubMed Web of Science ®Google Scholar
• Bonnet R. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob. Agents Chemother. 48(1), 1–14 (2004).
   PubMed Web of Science ®Google Scholar
• Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34(5), 634–640 (2002).
   PubMed Web of Science ®Google Scholar
• Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microb. Rev. 14(4), 933–951 (2001).
   PubMed Web of Science ®Google Scholar
• Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin. Microbiol. Infect. 8(6), 321–331 (2002).
   PubMed Web of Science ®Google Scholar
• Walsh T, Toleman MA, Poirel L, Nordmann P. Metallo-β-lactamases: the quiet before the storm? Clin. Microbiol. Rev. 18(2), 306–325 (2005).
   PubMed Web of Science ®Google Scholar
• Hooper DC. Efflux pumps and nosocomial antibiotic resistance: a primer for hospital epidemiologists. Clin. Infect. Dis. 40(12), 1811–1817 (2005).
   PubMed Web of Science ®Google Scholar
• Poole K. Efflux-mediated antimicrobial resistance. J. Antimicrob. Chemother. 56(1), 20–51 (2005).
   PubMed Web of Science ®Google Scholar
• Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44(12), 3322–3327 (2000).
   PubMed Web of Science ®Google Scholar
• Aeschlimann JR. The role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other Gram-negative bacteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 23(7), 916–924 (2003).
   PubMed Web of Science ®Google Scholar
• Hooper DC. Quinolone mode of action. Drugs 49(Suppl. 2), 10–15 (1995).
   PubMedGoogle Scholar
• Jalal S, Wretlind B. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microb. Drug Resist. 4(4), 257–261 (1998).
   PubMed Web of Science ®Google Scholar
• Poole K. Resistance to β-lactam antibiotics. Cell. Mol. Life Sci. 61(17), 2200–2223 (2004).
   PubMed Web of Science ®Google Scholar
• Rhomberg P, Jones RN, Mutnick A. Geographic variations and trends in key bacteremic pathogen resistance (R): report from the SENTRY Antimicrobial Surveillance Program (1997–2001). Proceedings of the 42nd Interscience Congress of Antimicrobial Agents and Chemotherapy. CA, USA (2002).
   Google Scholar
• Schiappa DA, Hayden MK, Matushek MG et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J. Infect. Dis. 174(3), 529–536 (1996).
   PubMed Web of Science ®Google Scholar
• Paterson DL. Recommendations for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin. Microbiol. Infect. 6(9), 460–463 (2000).
   PubMed Web of Science ®Google Scholar
• Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J. Antimicrob. Chemother. 52(3), 331–344 (2003).
   PubMed Web of Science ®Google Scholar
• Livermore DM. β-lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8(4), 557–584 (1995).
   PubMed Web of Science ®Google Scholar
• Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. J. Am. Med. Assoc. 289(7), 885–888 (2003).
   PubMed Web of Science ®Google Scholar
• Chow JW, Fine MJ, Shlaes DM et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann. Intern. Med. 115, 585–590 (1991).
   PubMed Web of Science ®Google Scholar
• Jones RN, Varnam DJ. Antimicrobial activity of broad spectrum agents tested against Gram-negative bacilli resistant to ceftazidime: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Diagn. Microbiol. Infect. Dis. 44(4), 379–382 (2002).
   PubMed Web of Science ®Google Scholar
• Sanders WE Jr, Tenney JH, Kessler RE. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin. Infect. Dis. 23(3), 454–461 (1996).
   PubMedGoogle Scholar
• Norrby SR. Carbapenems. Med. Clin. North Am. 79(4), 745–759 (1995).
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin. Infect. Dis. 32(Suppl. 2), S146–S155 (2001).
   PubMed Web of Science ®Google Scholar
• Fink MP, Snydman DR, Niederman MS et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem–cilastatin. The Severe Pneumonia Study Group. Antimicrob. Agents Chemother. 38(3), 547–557 (1994).
   PubMed Web of Science ®Google Scholar
• Masuda N, Ohya S. Cross-resistance to meropenem, cephems, and quinolones in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 36(9), 1847–1851 (1992).
   PubMed Web of Science ®Google Scholar
• Li XZ, Nikaido H, Poole K. Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39(9), 1948–1953 (1995).
   PubMed Web of Science ®Google Scholar
• Kohler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob. Agents Chemother. 43(2), 424–427 (1999).
   PubMed Web of Science ®Google Scholar
• Stover CK, Pham XQ, Erwin AL et al. Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 406(6799), 959–964 (2000).
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Karlowsky JA, Saunders MH et al. Development of multiple-antibiotic-resistant (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones. Antimicrob. Agents Chemother. 39(2), 489–495 (1995).
   PubMed Web of Science ®Google Scholar
• D’Agata EM. Rapidly rising prevalence of nosocomial multi-drug resistant, Gram-negative bacilli: a 9-year surveillance study. Infect. Control Hosp. Epidemiol. 25(10), 842–846 (2004).
   PubMedGoogle Scholar
• Andrade SS, Jones RN, Gales AC, Sader HS. Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997–2001). J. Antimicrob. Chemother. 52(1), 140–141 (2003).
   PubMed Web of Science ®Google Scholar
• Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am. J. Med. 87(5), 540–546 (1989).
   PubMed Web of Science ®Google Scholar
• Acharya A, Paterson D. Pseudomonas aeruginosa. In: Antimicrobial Therapy and Vaccines (Volume 1: Microbes). Yu V (Ed.). Apple Tree Productions, LLC, NY, USA, 549–562 (2002).
   Google Scholar
• Friedland I, Stinson L, Ikaiddi M, Harm S, Woods GL. Phenotypic antimicrobial resistance patterns in Pseudomonas aeruginosa and Acinetobacter: results of a Multicenter Intensive Care Unit Surveillance Study, 1995–2000. Diagn. Microbiol. Infect. Dis. 45(4), 245–250 (2003).
   PubMedGoogle Scholar
• Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multi-drug resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997–1999). Clin. Infect. Dis. 32(Suppl. 2), S104–S113 (2001).
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob. Agents Chemother. 47(5), 1681–1688 (2003).
   PubMed Web of Science ®Google Scholar
• Urban C, Segal-Maurer S, Rahal JJ. Considerations in control and treatment of nosocomial infections due to multi-drug resistant Acinetobacter baumannii. Clin. Infect. Dis. 36(10), 1268–1274 (2003).
   PubMed Web of Science ®Google Scholar
• Fernandez-Cuenca F, Martinez-Martinez L, Conejo MC, Ayala JA, Perea EJ, Pascual A. Relationship between β-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J. Antimicrob. Chemother. 51(3), 565–574 (2003).
   PubMed Web of Science ®Google Scholar
• Betriu C, Rodriguez-Avial I, Sanchez BA, Gomez M, Alvarez J, Picazo JJ. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob. Agents Chemother. 46(3), 892–895 (2002).
   PubMed Web of Science ®Google Scholar
• Higgins PG, Wisplinghoff H, Stefanik D, Seifert H. In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with β-lactams against epidemiologically characterized multi-drug resistant Acinetobacter baumannii strains. Antimicrob. Agents Chemother. 48(5), 1586–1592 (2004).
   PubMed Web of Science ®Google Scholar
• Levin AS, Levy CE, Manrique AE, Medeiros EA, Costa SF. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int. J. Antimicrob. Agents 21(1), 58–62 (2003).
   PubMed Web of Science ®Google Scholar
• Jellison TK, Mckinnon PS, Rybak MJ. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam. Pharmacotherapy 21(2), 142–148 (2001).
   PubMed Web of Science ®Google Scholar
  Winslow R. Orphan rescue: how small firms sometimes hit big with drug discards. Wall St J. August 11 (2003).
   Google Scholar